Recruitment

Recruitment Status
Terminated
Estimated Enrollment
91

Summary

Conditions
  • BRAF Mutated Melanoma
  • Metastatic Pancreatic Adenocarcinoma
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: Non-RandomizedMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT01562899
Collaborators
Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer